gefitinib has been researched along with rilpivirine in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (rilpivirine) | Trials (rilpivirine) | Recent Studies (post-2010) (rilpivirine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 580 | 93 | 513 |
| Protein | Taxonomy | gefitinib (IC50) | rilpivirine (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.068 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 6.1612 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.7406 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3635 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.2818 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.3363 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.5 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.0759 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for gefitinib and rilpivirine
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |